Some COVID-19 Vaccines Could Work Better on One Patient Population than Others, Says Dr. Anthony Fauci
By HospiMedica International staff writers Posted on 29 Sep 2020 |
Illustration
Among the four COVID-19 vaccines in the final stage of US clinical trials and another one about the enter Phase 3, few of them could hold promise in some patient populations better than others.
Speaking to Dr. Howard Bauchner, editor of JAMA during a recent interview, Dr. Anthony Fauci who is the director of the National Institute of Allergy and Infectious Diseases, said that as the COVID-19 vaccines receive approval, researchers could discover that one works better on one population than others. The different COVID-19 vaccines will provide several options should one not be as effective as another.
The four COVID-19 vaccines that are in final-stage US clinical trials are being developed by Moderna, Pfizer, Johnson & Johnson and AstraZeneca. The fifth vaccine against COVID-19 from Novavax has begun Phase 3 clinical trials in the UK.
“There may be different vaccines for different situations,” Fauci told JAMA’s Bauchner. “You might find when you do a clinical trial, that you maybe have three or four vaccines that are effective.”
“But you may find one that does better in an older population than another,” Fauci added. “It could be that you would recommend, that if you are an older person you get this vaccine versus that. That is something we wish for namely that we have enough vaccines that you can tailor the better one for each individual group.”
Speaking to Dr. Howard Bauchner, editor of JAMA during a recent interview, Dr. Anthony Fauci who is the director of the National Institute of Allergy and Infectious Diseases, said that as the COVID-19 vaccines receive approval, researchers could discover that one works better on one population than others. The different COVID-19 vaccines will provide several options should one not be as effective as another.
The four COVID-19 vaccines that are in final-stage US clinical trials are being developed by Moderna, Pfizer, Johnson & Johnson and AstraZeneca. The fifth vaccine against COVID-19 from Novavax has begun Phase 3 clinical trials in the UK.
“There may be different vaccines for different situations,” Fauci told JAMA’s Bauchner. “You might find when you do a clinical trial, that you maybe have three or four vaccines that are effective.”
“But you may find one that does better in an older population than another,” Fauci added. “It could be that you would recommend, that if you are an older person you get this vaccine versus that. That is something we wish for namely that we have enough vaccines that you can tailor the better one for each individual group.”
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans